Elixiron Immunotherapeutics Inc.

Elixiron Immunotherapeutics is a clinical-stage biotechnology company dedicated to developing precision immunotherapies targeting neuroinflammation and autoimmune diseases. Leveraging decades of expertise in immunology and drug development, Elixiron has advanced two promising drug candidates into clinical trials: Enrupatinib, a CSF-1R inhibitor designed to modulate brain microglia and mitigate neuroinflammation for Alzheimer's disease; and Indemakitug, a next-generation anti-IFN-γ antibody developed to address immune dysregulation in vitiligo. The company is a two-time recipient of the Alzheimer’s Association's "Part the Cloud" award and has successfully established two licensing collaborations. Looking ahead, Elixiron remains committed to translating visionary scientific discoveries into clinically valuable therapies, aiming to provide more effective treatment options for patients worldwide.